SAN DIEGO, Jan 11, 2010 (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ:ILMN) today announced the HumanOmniExpress BeadChip (OmniExpress), the newest addition to the Omni family of microarrays for genome-wide association studies (GWAS). Designed as a 12-sample Beadchip, OmniExpress allows interrogation of over 700,000 variants per sample totaling more than eight million available data points on a single chip. Coupled with the Illumina iScan System, OmniExpress enables processing of more than 1,400 samples per week, the highest throughput in the industry.
The markers on OmniExpress are a subset of the content powering Illumina's flagship GWAS product, the HumanOmni1-Quad, and incorporate an optimized set of SNPs chosen from all three phases of the International HapMap Project. As with the HumanOmni1, researchers starting with OmniExpress can take advantage of future supplemental Omni BeadChips containing new content derived from the 1000 Genomes Project. Priced at $250 (USD) per sample, OmniExpress offers a compelling entry point to the next generation of Illumina Omni arrays.
"The OmniExpress is an extension of the Omni family of microarrays and provides the same high quality data as the Omni1 at a price that is among the most competitive in the industry," said Jay Flatley, president and CEO of Illumina. "OmniExpress, and the recently announced BovineHD BeadChip, are the first two products incorporating Illumina's 3rd generation array technology, delivering even more content, formats, and flexibility to researchers."
The combination of a multi-sample format, proven assay and intelligently-selected content of OmniExpress offers several key benefits:
- Premiere Genomic Coverage - Greater than 700,000 strategically selected tagSNPs provide genomic coverage up to 90% for Caucasian and Asian populations as assessed by the International HapMap Project.
- Proven Data Quality - Industry-standard Infinium HD Assay affords greater than 99% average call rates and greater than 99.9% reproducibility.
- Industry Best Throughput - With the iScan System, researchers can process in excess of thousands of samples per week.
As with all other Infinium HD products, the OmniExpress BeadChip supports copy number variation (CNV) analyses for disease-association studies and is compatible with Illumina's automation solutions. First customer shipments of the OmniExpress are expected in the first quarter of 2010.
For more information about the HumanOmniExpress BeadChip, please visit our website at http://www.illumina.com/OmniExpress.
About the Infinium Genotyping Assay
Illumina continues to lead the industry in cutting-edge genotyping technologies with a new generation of high-density, multi-sample Infinium HD products that support integrated SNP genotyping and copy number variation (CNV) analysis. Infinium HD BeadChips deliver the industry's best data quality with the highest call rates and reproducibility for genome-wide association studies, plus low noise for precise copy number measurements. Multi-sample Infinium HD BeadChips and rapid assay readout with the iScan System provides the fastest path to discovery and publication.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.
Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected shipping date for the OmniExpress. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in new product development and manufacturing and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors:
Peter J. Fromen, 858-202-4507
Sr. Director, Investor Relations
pfromen@illumina.com
Media:
Wilson Grabill, 858-882-6822
Senior Manager, Public Relations
wgrabill@illumina.com
